NAD+ vs SHLP2

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

NAD+

Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every living cell. It plays a central role in energy metabolism, DNA repair, gene expression, and cellular signaling. NAD+ levels naturally decline with age, and restoring them has become a major focus of longevity research. Injectable NAD+ bypasses the GI tract for higher bioavailability compared to oral precursors like NMN or NR.

Full details →

SHLP2

SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.

Full details →

Side-by-Side Comparison

Aspect	NAD+	SHLP2
Dose Range	20 mg–120 mg	1 mg–5 mg
Frequency	Less than daily	1x daily
Cycle Length	4–12 weeks	4–8 weeks
Route	subcutaneous	subcutaneous
Mechanism	NAD+ is a critical substrate for sirtuins (SIRT1-7), a family of enzymes involved in DNA repair, inflammation regulation, and mitochondrial function. It also serves as a coenzyme for PARP enzymes (involved in DNA damage repair) and CD38 (involved in immune cell signaling). By directly replenishing cellular NAD+ pools, injectable NAD+ supports mitochondrial electron transport chain function, enhances ATP production, and activates longevity-associated pathways.	Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways.
Typical Dosage	Subcutaneous injection, typically 2–3 times per week. Start low and escalate: Twice per week protocol: Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 120 mg maintenance (0.6 ml). Three times per week protocol (e.g. Mon/Wed/Fri): Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 80 mg maintenance (0.4 ml). Volumes above assume 200 mg/ml concentration (100 mg vial reconstituted with 0.5 ml BAC water). Inject slowly — rapid administration increases flushing and nausea. Avoid back-to-back injection days. IV infusion (clinical setting): 250–750 mg per session over 2–4 hours.	Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established.
Administration	Subcutaneous injection is the most practical route for self-administration. Inject slowly — rapid administration increases side effects (flushing, chest tightness, nausea). Some users split larger doses across multiple daily injections to improve tolerance. IV infusions provide the highest bioavailability but require a clinical setting. Store reconstituted NAD+ refrigerated and protect from light. NAD+ solutions are pH-sensitive; use bacteriostatic water for reconstitution.	Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties.
Side Effects	Flushing and warmth (very common, especially at higher doses or fast injection rates). Nausea and mild GI discomfort. Chest tightness or pressure during injection (usually transient). Injection site pain or redness. Headache. These side effects are typically dose-dependent and diminish with slower administration and repeated use.	Limited data. Animal studies suggest good tolerability. May affect glucose metabolism.
Best For	Anti-Aging & Longevity Cognitive Performance Recovery & Healing	Fat Loss Anti-Aging & Longevity